NCT06859788View on ClinicalTrials.gov

SPI-1005 for the Treatment of Meniere's Disease (Open Label)

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Meniere's DiseaseMénière's Disease
Interventions
DRUG

Ebselen

Glutathione peroxidase mimetic

Trial Locations (5)

10017

NOT_YET_RECRUITING

ENT and Allergy Associates, LLP, New York

29425

RECRUITING

Medical University of South Carolina, Charleston

33136

NOT_YET_RECRUITING

University of Miami, Miami

33487

RECRUITING

ENT and Allergy Associates of Florida, Boca Raton

75390

NOT_YET_RECRUITING

University of Texas Southwestern, Dallas

All Listed Sponsors
lead

Sound Pharmaceuticals, Incorporated

INDUSTRY

NCT06859788 - SPI-1005 for the Treatment of Meniere's Disease (Open Label) | Biotech Hunter | Biotech Hunter